Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Extension Study in GCA (France)
NCT03202368Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2017
- Primary completion
- Aug 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in giant cell arteritis (GCA), sponsored by Roche. Primary endpoint: Percentage of subjects with Adverse Events. Started Oct 2017; status: completed.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03202368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03202368.